Coronary Bypass Grafting With Minimal Extracorporeal Circulation System Versus Off-pump Coronary Surgery
- Conditions
- Coronary Artery Disease
- Interventions
- Procedure: Off-pump coronary artery bypass graftProcedure: Mini extracorporeal circulation bypass
- Registration Number
- NCT02118025
- Lead Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Brief Summary
The investigators aimed to evaluate the clinical results and the inflammatory response of the minimal extracorporeal circulation system (MECC) Compared with off-pump coronary revascularization (OPCABG).
This is a randomized and prospective study in 230 patients with indications for coronary surgery, with 113 patients in the OPCABG group and 117 in the MECC group. The endpoints were the clinical and biochemical results, intra-operative outcomes and the determination of 19 inflammatory circulating markers, 17 of them for the first time analyzed comparing both techniques.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 230
- Indication for coronary surgery established on the basis of current published guidelines
- Documented preoperative systemic proinflammatory status and/or steroid administration within 6 months before surgery.
- Coexistence of a cardiomyopathy different than coronary artery disease that precise surgical treatment.
- Left ventricle ejection fraction of 40% or less.
- Treatment with erythropoietin (EPO) three months before the intervention
- Hematocrit less than 35% the day prior to the procedure
- Redo surgery
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Off-pump coronary artery bypass graft Off-pump coronary artery bypass graft Patients operated on with off-pump coronary artery bypass graft, beating heart surgery. Mini extracorporeal circulation bypass Mini extracorporeal circulation bypass Patients operated on with mini extracorporeal circulation bypass. A modified extracorporeal system.
- Primary Outcome Measures
Name Time Method Clinical outcomes within the first 30 days (plus or minus 3 days) after surgery Number of Participants with Adverse Events, e.g, renal failure, atrial fibrillation, acute myocardial infarct, stroke, redo surgery, death.
- Secondary Outcome Measures
Name Time Method Determination of increase over the first 48 hours of plasma levels of 19 circulating markers of inflammatory response. Area Under the Concentration-Time Curve (AUC 0-48 hours) Determination of increase over the first 48 hours after the operation of plasma levels of 19 circulating markers of inflammatory response. The levels of inflammatory markers are measured in pg / mL and subsequently, the increase over the 48 hours is determined with the area under the curve.
Biochemical outcomes Within the first 30 days (plus or minus 3 days) after surgery Changes in creatine kinase levels, troponin levels, glucose, leukocytes, platelets, hemoglobin and hematocrit levels. From basal point to 48 hours time after surgery.
Operative results Within the first 30 days (plus or minus 3 days) after surgery Total hospitalization time (days)
Trial Locations
- Locations (1)
Hospital de la Santa Creu i Sant Pau
🇪🇸Barcelona, Spain